Boron Accumulation in Brain Tumor Cells through Boc-Protected Tryptophan as a Carrier for Boron Neutron Capture Therapy
摘要:
Boron neutron capture therapy (BNCT) is a binary therapeutic approach. Nonradioactive boron-10 atoms accumulated in tumor cells combining with the neutron beams produce two highly energetic particles that could eradicate the cell that takes it and the neighboring cells. Small molecules that carry boron atom, e.g. 5- and 6-boronated and 2,7-diboronated tryptophans, were assessed for their boron accumulation in U87-MG, LN229, and 3T3 for BNCT. TriBoc tryptophan, TB-6-BT, shows boron-10 at 300 ppm in both types of tumor cells with a tumor to normal ratio (T/N) of 5.19-5.25 (4 h). TB-5-BT and DBA-5-BT show boron-10 at 300 ppm (2 h) in U87-MG cells. TB-5-BT exerts a T/N of >9.66 (1 h) in LN229 compared with the current clinical boronophenyl alanine with a highest T/N of 2.3 (1 h) and accumulation concentration of <50 ppm. TB-5-BT and TB-6-BT warrant further animal study.
Amino acid derivatives and use thereof as nep, ace and ece inhibitors
申请人:——
公开号:US20030055086A1
公开(公告)日:2003-03-20
Compounds of formula (I):
1
wherein
0≦n≦3,
0≦m≦6,
R
3
and R
4
together form a phenyl ring,
B represents a heteroaryl group,
R
1
and R
2
represent a hydrogen atom or groups as defined in the description.
INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5)
申请人:Vennemann Matthias
公开号:US20110027226A1
公开(公告)日:2011-02-03
Compounds of a certain formula I, in which R1, R2, R3 and R4 have the meanings indicated in the description, are effective Eg5-inhibiting compounds with anti-proliferative and/or apoptosis inducing activity.
Compounds of a certain formula I, in which R1, R2, R3 and R4 have the meanings indicated in the description, are effective Eg5-inhibiting compounds with anti-proliferative and/or apoptosis inducing activity.
某式 I 的化合物(其中 R1、R2、R3 和 R4 的含义如描述所示)是有效的 Eg5 抑制化合物,具有抗增殖和/或诱导细胞凋亡的活性。
US6716852B2
申请人:——
公开号:US6716852B2
公开(公告)日:2004-04-06
Irie, Kunihiko; Ishida, Akihiko; Nakamura, Tohru, Chemical and pharmaceutical bulletin, 1984, vol. 32, # 6, p. 2126 - 2139